Association between cytokine single nucleotide polymorphisms (SNPs), disease response, and/or cytokine release syndrome (CRS) in relapsed/refractory B-Cell Acute Lymphoblastic Leukemia patients receiving Blinatumomab.
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacodynamics; Pharmacogenomic
Most Recent Events
- 18 Jan 2019 New trial record
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology